N/A
Completed N=53
Piloting Pathways With Lung Cancer Patients
Source: ClinicalTrials.gov NCT04161157 ↗Enrolled (actual)
53
Serious AEs
0.0%
Results posted
Oct 2023
Primary outcomePrimary: Feasibility of Enrollment: Percentage of Eligible and Approached Patients Who Agree to Participate — 53 Participants
Summary
The purpose of this research is to determine the feasibility of a new supportive intervention, called Pathways, for patients with advanced stage and metastatic lung cancer.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Feasibility of Enrollment: Percentage of Eligible and Approached Patients Who Agree to Participate |
53 | — |
| PRIMARY Acceptability: Ratings |
8.79; 8.46; 8.54 | — |
| SECONDARY PROMIS Satisfaction With Participation in Social Roles - Short Form 8a |
21.8 | — |
| SECONDARY Hope - State Hope Scale (Snyder) |
31.3 | — |
| SECONDARY Purpose - PROMIS Meaning and Purpose 4a |
16.4 | — |
| SECONDARY Distress - PROMIS Depression Short Form 6a |
11.3 | — |
| SECONDARY Lung Cancer Stigma - Lung Cancer Stigma Inventory (Hamann) |
52 | — |
Eligibility Criteria
Inclusion Criteria
- new or recurrent stage IIIB, stage IIIC or stage IV non-small cell lung cancer (NSCLC) or extensive stage SCLC
- 18 years of age or older
- ECOG PS 0-2/Karnofsky 60-100
- 3 to 12 weeks into active cancer treatment
Exclusion Criteria
- unstable brain metastases
- cognitive or psychiatric condition for which participating would be inappropriate
- unable to speak and read English
Data sourced from ClinicalTrials.gov (NCT04161157). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.